drugset / Trial / NCT02285036
Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children
Phase 3
Completed
1660 enrolled
Walvax Biotechnology Co., Ltd.
Air Force Military Medical University, China · collabGuangxi Center for Disease Control and Prevention · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
A newly 23-valent pneumococcal polysaccharide vaccine was developed with promising safety and immunogenicity demonstrated in the phase III trial in China. A large scale, double blind, randomized, PNEUMOVAX 23 (Merck \& Co., Inc.) controlled phase 3 clinical trial was conducted.
Timeline
- Start
- 2012-09
- Primary completion
- 2012-12
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pneumovax 23 | Vaccine | 0.5 ml | Intramuscular |